Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role

References

• Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22(3):396–414.
   PubMed Web of Science ®Google Scholar
• Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13(4):602–614.
   PubMed Web of Science ®Google Scholar
• Vani J, Elluru S, Negi VS, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev. 2008;7(6):440–444.
   PubMed Web of Science ®Google Scholar
• Sanna PP, Burton DR. Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts. J Virol. 2000;74(21):9813–9817.
   PubMed Web of Science ®Google Scholar
• Cross AS. Intravenous immunoglobins (IVIGs) to prevent and treat infectious diseases. Adv Exp Med Biol. 1995;383:123–130.
   PubMedGoogle Scholar
• Bebbington C, Yarranton G. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol. 2008;19(6):613–619.
   PubMed Web of Science ®Google Scholar
• Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol. 1994;97(Suppl 1):79–83.
   PubMed Web of Science ®Google Scholar
• Roux E, Yersin A. Contribution à l’étude de la diphthérie. Ann Inst Pasteur. 1888;2:629–661.
   Google Scholar
• Roux ME, Martin ML. A contribution to the study of diphtheria: (serum-therapeutics.). J Comp Pathol Ther. 1894;7(0):332–355.
   Google Scholar
• Armstrong S. The serum treatment of diphtheria. Popular Sci. 1895;XLVI(46):512–522.
   Google Scholar
• Von Behring E, Kitasato S. Ueber das zustandekommen der diphtherie-immunität und der tetanus-immunität bei thieren. Dtsch Med Wochenschr. 1890;16(49):1113–1114.
   Google Scholar
• Behring E, Wernicke E. Ueber immunisierung und heilung von versuchsthieren bei der diphtherie. Zeitschrift Für Hygiene Und Infections-Krankheiten. 1892;12:10–44.
   Google Scholar
• Babes V, Lepp R. Recherches sur le vaccination antirabique. Ann Inst Pasteus. 1889;3:385.
   Google Scholar
• Babes V, Cerchez T. Action sur le virus rabique du sang du chien réfracaire à la rage. Ann Inst Pasteus. 1891;10:630.
   Google Scholar
• Ehrlich P. Experimentelle untersuchungen über immunität. I Ueber Ricin Dtsch Med Wochenschr. 1891;17(32):976–979.
   Google Scholar
• Ehrlich P. Experimentelle untersuchungen über immunität. II. Ueber abrin. Dtsch Med Wochenschr. 1891;17(44):1218–1219.
   Google Scholar
• Ehrlich P, Kossel H, Wassermann A. Ueber gewinnung und verwendung des diphterieheilserums. Dtsch Med Wochenschr. 1894;20:353–355.
   Google Scholar
• Cenci F. Alcune esperienze di sieroimmunizzazione e sieroterapia nel morbillo. Riv Clin Pediatr. 1907;5:1017–1025.
   Google Scholar
• Gibson RB. The concentration of antitoxin for therapeutic use. J Biol Chem. 1906;1(2):161–170.
   Google Scholar
• Karelitz S. Prophylaxis against measles with the globulin fraction of immune human adult serum. Am J Dis Child. 1938;55(4):768–775.
   Google Scholar
• Wolff-Eisner A. Handbuch der serumtherapie und experimentellen therapie: ein handbuch für klinik und praxis. Vol. 1. München: J.F. Lehmanns; 1910.
   Google Scholar
• Wever PC, van Bergen L. Prevention of tetanus during the First World War. Med Humanit. 2012;38(2):78–82.
   PubMed Web of Science ®Google Scholar
• Heidelberger M, Pedersen KO. The molecular weight of antibodies. J Exp Med. 1937;65(3):393–414.
   PubMedGoogle Scholar
• Tiselius A, Kabat EA. Electrophoresis of immune serum. Science. 1938;87(2262):416–417.
   PubMedGoogle Scholar
• Duran Jorda F. The Barcelona blood-transfusion service. Lancet. 1939;233(6031):773–775.
   Google Scholar
• Cohn EJ, Luetscher JA, Oncley JL, et al. Preparation and properties of serum and plasma proteins. III. Size and charge of proteins separating upon equilibration across membranes with ethanol-water mixtures of controlled pH, ionic strength and temperature. J Am Chem Soc; 12/1/1940: American Chemical Society. 1940;62:3396–3400.
   Google Scholar
• Cohn EJ, Strong LE, Hughes WL, et al. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459–475.
   PubMed Web of Science ®Google Scholar
• Cohn EJ, Oncley JL, Strong LE, et al. Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma. J Clin Invest. 1944;23(4):417–432.
   PubMedGoogle Scholar
• Cohn EJ. Blood proteins and their therapeutic value. Science. 1945;101(2612):51–56.
   PubMed Web of Science ®Google Scholar
• Barandun S, Kistler P, Jeunet F, et al. Intravenous administration of human gamma-globulin. Vox Sang. 1962;7:157–174.
   PubMed Web of Science ®Google Scholar
• Grifols-Lucas JA. Use of plasmapheresis in blood donors. Br Med J. 1952;1(4763):854.
   PubMed Web of Science ®Google Scholar
• Neefe JR, Stokes J. An epidemic of infectious hepatitis apparently due to a water borne agent. JAMA. 1945;128:1063–1075.
   Web of Science ®Google Scholar
• Gellis SS, Stokes J, Brother GM, et al. The use of human immune serum globulin (gamma globulin) in infectious (epidemic) hepatitis in the mediterranean theater of operations. I. Studies on prophylaxis in two epidemics of infectious hepatitis. JAMA. 1945;128:1062–1063.
   Web of Science ®Google Scholar
• Havens WPJ, Paul JR. Prevention of infectious hepatitis with gamma globulin. J Am Med Assoc. 1945;129(4):270–272.
   Web of Science ®Google Scholar
• Woodson RD, Clinton JJ. Hepatitis prophylaxis abroad. Effectiveness of immune serum globulin in protecting Peace Corps volunteers. JAMA. 1969;209(7):1053–1058.
   PubMed Web of Science ®Google Scholar
• Hammon WM, Coriell LL, Stokes JJ. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. I. Plan of controlled field tests and results of 1951 pilot study in Utah. J Am Med Assoc. 1952;150(8):739–749.
   PubMed Web of Science ®Google Scholar
• Hammon WM, Coriell LL, Stokes JJ. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. 2. Conduct and early follow-up of 1952 Texas and Iowa-Nebraska studies. J Am Med Assoc. 1952;150(8):750–756.
   PubMed Web of Science ®Google Scholar
• Hammon WM, Coriell LL, Wehrle PF, et al. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. 3. Preliminary report of results based on clinical diagnosis. J Am Med Assoc. 1952;150(8):757–760.
   PubMed Web of Science ®Google Scholar
• Kempe CH, Bowles C, Meiklejohn G, et al. The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull World Health Organ. 1961;25:41–48.
   PubMed Web of Science ®Google Scholar
• Amer J, Ott E, Ibbott FA, et al. The effect of monthly gamma-globulin administration on morbidity and mortality from infection in premature infants during the first year of life. Pediatrics. 1963;32:4–9.
   PubMed Web of Science ®Google Scholar
• Garces H, Munoz R, Fernandez F. Infection in premature infants. Rev Chil Pediatr. 1954;25(3):109–118.
   PubMedGoogle Scholar
• Steen JA. Gamma globulin in preventing infections in premature infants. Arch Pediatr. 1960;77:291–294.
   Google Scholar
• Mozen MM, Schroeder DD, Cabasso VJ. A new immune serum globulin preparation for intravenous administration (author’s transl). Arzneimittelforschung. 1980;30(9):1484–1486.
   PubMed Web of Science ®Google Scholar
• WHO Model List of Essential Medicines (19th List), (2015). [cited 2015 Apr]. Available from: http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1
   Google Scholar
• Kark JD. Pre-exposure prophylaxis with immune serum globulin for prevention of viral hepatitis in army recruits. J Epidemiol Community Health. 1982;36(3):176–182.
   PubMed Web of Science ®Google Scholar
• Kark JD. Pre-exposure prophylaxis of viral hepatitis with immune serum globulin in an endemic area. A trial in field units of the Israel defence forces. Scand J Infect Dis. 1983;15(1):3–6.
   PubMed Web of Science ®Google Scholar
• Lerman Y, Shohat T, Ashkenazi S, et al. Efficacy of different doses of immune serum globulin in the prevention of hepatitis A: a three-year prospective study. Clin Infect Dis. 1993;17(3):411–414.
   PubMed Web of Science ®Google Scholar
• Victor JC, Monto AS, Surdina TY, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med. 2007;357(17):1685–1694.
   PubMed Web of Science ®Google Scholar
• Al-Hemsi B, McGory RW, Shepard B, et al. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplant. 1996;10(6 Pt 2):668–675.
   PubMed Web of Science ®Google Scholar
• Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother. 1987;31(12):1882–1886.
   PubMed Web of Science ®Google Scholar
• The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99(1):93–99.
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 1993;329(21):1524–1530.
   PubMed Web of Science ®Google Scholar
• Meyers JD, Leszczynski J, Zaia JA, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med. 1983;98(4):442–446.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987;317(17):1049–1054.
   PubMed Web of Science ®Google Scholar
• King SM, Superina R, Andrews W, et al. Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. Clin Infect Dis. 1997;25(5):1173–1179.
   PubMed Web of Science ®Google Scholar
• Lambert JS, Mofenson LM, Fletcher CV, et al. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis. 1997;175(2):283–291.
   PubMed Web of Science ®Google Scholar
• Onyango-Makumbi C, Omer SB, Mubiru M, et al. Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr. 2011;58(4):399–407.
   PubMed Web of Science ®Google Scholar
• Agostini G, Agostini S. Immunoglobulins in the treatment of herpes zoster. La Clinica Terapeutica. 1992;141(9 Pt 2):11–16.
   PubMedGoogle Scholar
• Elsterova J, Palus M, Sirmarova J, et al. Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin. Ticks Tick Borne Dis. 2017;8(2):253–258.
   PubMed Web of Science ®Google Scholar
• Masci S, De Simone C, Famularo G, et al. Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: a clinical and immunological study. Immunopharmacol Immunotoxicol. 1995;17(1):33–47.
   PubMed Web of Science ®Google Scholar
• Briassoulis G, Papadopoulos G, Zavras N, et al. Cardiac troponin I in fulminant adenovirus myocarditis treated with a 24-hour infusion of high-dose intravenous immunoglobulin. Pediatr Cardiol. 2000;21(4):391–394.
   PubMed Web of Science ®Google Scholar
• Park UJ, Hyun SK, Kim HT, et al. Successful treatment of disseminated adenovirus infection with ribavirin and intravenous immunoglobulin in an adult renal transplant recipient: a case report. Transplant Proc. 2015;47(3):791–793.
   PubMed Web of Science ®Google Scholar
• Kerensky T, Hasan A, Schain D, et al. Histopathologic resolution of adult liver transplantation adenovirus hepatitis with cidofovir and intravenous immunoglobulin: a case report. Transplant Proc. 2013;45(1):293–296.
   PubMed Web of Science ®Google Scholar
• Saquib R, Melton LB, Chandrakantan A, et al. Disseminated adenovirus infection in renal transplant recipients: the role of cidofovir and intravenous immunoglobulin. Transpl Infect Dis. 2010;12(1):77-83.
   Google Scholar
• Randhawa P, Pastrana DV, Zeng G, et al. Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of Polyomavirus BK. Am J Transplant. 2015;15(4):1014–1020.
   PubMed Web of Science ®Google Scholar
• Gacouin A, Bourhy H, Renaud JC, et al. Human rabies despite postexposure vaccination. Eur J Clin Microbiol Infect Dis. 1999;18(3):233–235.
   PubMed Web of Science ®Google Scholar
• Cabasso VJ, Loofbourow JC, Roby RE, et al. Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects. Bull World Health Organ. 1971;45(3):303–315.
   PubMed Web of Science ®Google Scholar
• Crawford RJ, Morgan M, Mitchell R. A regional programme to collect plasma for preparation of human immunoglobulin anti-rabies. J Clin Pathol. 1980;33(2):180–182.
   PubMed Web of Science ®Google Scholar
• Zaaijer HL, Leentvaar-Kuijpers A, Rotman H, et al. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization. J Med Virol. 1993;40(1):22–27.
   PubMed Web of Science ®Google Scholar
• Shouval D, Ashur Y, Adler R, et al. Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin. J Hepatol. 1993;18(Suppl 2):S32–S7.
   Google Scholar
• Anderson RD, Chinnakotla S, Guo L, et al. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant. 2007;21(4):510–517.
   PubMed Web of Science ®Google Scholar
• Marzano A, Marengo A, Andreone P, et al. Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. Minerva Med. 2010;101(6):373–383.
   PubMed Web of Science ®Google Scholar
• Singham J, Greanya ED, Lau K, et al. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol. 2010;9(2):166–171.
   PubMed Web of Science ®Google Scholar
• Hemming VG, Prince GA, Horswood RL, et al. Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J Infect Dis. 1985;152(5):1083–1087.
   PubMed Web of Science ®Google Scholar
• Prince GA, Hemming VG, Horswood RL, et al. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 1985;3(3):193–206.
   PubMed Web of Science ®Google Scholar
• Gupta N, LeGoff J, Chamat S, et al. Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity. PLoS One. 2013;8(7):e69390.
   Google Scholar
• Rodriguez WJ, Gruber WC, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics. 1997;100(6):937–942.
   PubMed Web of Science ®Google Scholar
• Rodriguez WJ, Gruber WC, Welliver RC, et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics. 1997;99(3):454–461.
   PubMed Web of Science ®Google Scholar
• Nigro G, Adler SP, La Torre R, et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005;353(13):1350–1362.
   PubMed Web of Science ®Google Scholar
• Revello MG, Lazzarotto T, Guerra B, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014;370(14):1316–1326.
   PubMed Web of Science ®Google Scholar
• Condie RM, O’Reilly RJ. Prevention of cytomegalovirus infection in bone marrow transplant recipients by prophylaxis with an intravenous, hyperimmune cytomegalovirus globulin. Birth Defects Orig Artic Ser. 1984;20(1):327–344.
   PubMedGoogle Scholar
• Reed EC, Bowden RA, Dandliker PS, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109(10):783–788.
   PubMed Web of Science ®Google Scholar
• Séchet A, Bridoux F, Bauwens M, et al. Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins. Transplant Proc. 2002;34(3):812–813.
   PubMed Web of Science ®Google Scholar
• Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy. 2010;30(6):554–561.
   PubMed Web of Science ®Google Scholar
• Czer LS, Ruzza A, Vespignani R, et al. Prophylaxis of cytomegalovirus disease in mismatched patients after heart transplantation using combined antiviral and immunoglobulin therapy. Transplant Proc. 2011;43(5):1887–1892.
   PubMed Web of Science ®Google Scholar
• Cummins LM, Weinhold KJ, Matthews TJ, et al. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood. 1991;77(5):1111–1117.
   PubMed Web of Science ®Google Scholar
• Mofenson LM, Moye JJ, Korelitz J, et al. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Pediatr Infect Dis J. 1994;13(6):477–484.
   PubMed Web of Science ®Google Scholar
• Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med. 1994;331(18):1181–1187.
   PubMed Web of Science ®Google Scholar
• Ait-Khaled M, Lyall EG, Stainsby C, et al. Intrapartum mucosal exposure to human immunodeficiency virus type 1 (HIV-1) of infants born to HIV-1-infected mothers correlates with maternal plasma virus burden. J Infect Dis. 1998;177(4):1097–1100.
   PubMed Web of Science ®Google Scholar
• Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis. 1999;179(3):567–575.
   PubMed Web of Science ®Google Scholar
• Stiehm ER, Fletcher CV, Mofenson LM, et al. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J Infect Dis. 2000;181(2):548–554.
   PubMed Web of Science ®Google Scholar
• Senneville E, Chidiac C, Brouillard M, et al. Acyclovir and specific anti-varicella-herpes zoster immunoglobulins in the treatment of varicella-zoster virus infection in 113 adults. Pathologie-Biologie. 1990;38(5(Pt 2)):568–571.
   PubMed Web of Science ®Google Scholar
• Huang YC, Lin TY, Lin YJ, et al. Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella. Eur J Pediatr. 2001;160(2):91–94.
   PubMed Web of Science ®Google Scholar
• Saenz-Farret M, Sandoval-Rodriguez V, Paz-Navarro CE, et al. Successful treatment of brachial plexopathy due to herpes zoster infection with intravenous immunoglobulin. Clin Neuropharmacol. 2017;40(1):43–47.
   PubMed Web of Science ®Google Scholar
• Ruzek D, Dobler G, Niller HH. May early intervention with high dose intravenous immunoglobulin pose a potentially successful treatment for severe cases of tick-borne encephalitis? BMC Infect Dis. 2013;13:306.
   PubMed Web of Science ®Google Scholar
• Emovon OE, Lin A, Howell DN, et al. Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. Nephrol Dial Transplant. 2003;18(11):2436–2438.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Supasa P, Wongwiwat W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17(9):1102–1108.
   PubMed Web of Science ®Google Scholar
• Takada A, Feldmann H, Ksiazek TG, et al. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003;77(13):7539–7544.
   PubMed Web of Science ®Google Scholar
• Stettler K, Beltramello M, Espinosa DA, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823–826.
   PubMed Web of Science ®Google Scholar
• Hung IF, To KK, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection. Chest. 2013;144(2):464–473.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Hajeer AH, Luke T, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22(9):1554–1561.
   PubMed Web of Science ®Google Scholar
• Ben-Nathan D, Lustig S, Tam G, et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis. 2003;188(1):5–12.
   PubMed Web of Science ®Google Scholar
• Ben-Nathan D, Gershoni-Yahalom O, Samina I, et al. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis. 2009;9:18.
   PubMed Web of Science ®Google Scholar
• Salehi H, Salehi M, Adibi N, et al. Comparative study between Ribavirin and Ribavirin plus intravenous immunoglobulin against Crimean Congo hemorrhagic fever. J Res Med Sci. 2013;18(6):497–500.
   PubMed Web of Science ®Google Scholar
• Frame JD, Verbrugge GP, Gill RG, et al. The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg. 1984;78(3):319–324.
   PubMed Web of Science ®Google Scholar
• Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979;2(8154):1216–1217.
   PubMed Web of Science ®Google Scholar
• Couderc T, Khandoudi N, Grandadam M, et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009;200(4):516–523.
   PubMed Web of Science ®Google Scholar
• Leite Gouveia F, Mendes Batista de Oliveira R, Edson De Souza Lucena A, et al. Production of intravenous human dengue immunoglobulin from Brazilian-blood donors. Braz J Pharm Sci. 2013;49(4):821–829.
   Web of Science ®Google Scholar
• van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33–42.
   PubMed Web of Science ®Google Scholar
• Dowd KA, DeMaso CR, Pelc RS, et al. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Rep. 2016;16(6):1485–1491.
   PubMed Web of Science ®Google Scholar
• Cao RY, Han JF, Jiang T, et al. In vitro and in vivo characterization of a new enterovirus type 71-specific human intravenous immunoglobulin manufactured from selected plasma donors. J Clin Virol. 2011;51(4):246–249.
   PubMed Web of Science ®Google Scholar
• Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599–609.
   PubMed Web of Science ®Google Scholar
• Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447–456.
   PubMed Web of Science ®Google Scholar
• Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J. 2006;12(6):489.
   PubMedGoogle Scholar
• Wong HK, Lee CK, Hung IF, et al. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion. 2010;50(9):1967–1971.
   PubMed Web of Science ®Google Scholar
• Chong JL, Sapari S, Kuan YC. A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G. J Microbiol Immunol Infect. 2011;44(4):319–322.
   PubMedGoogle Scholar
• Gordon CL, Langan K, Charles PG, et al. Pooled human immunoglobulin therapy in critically Ill patients with pandemic 2009 influenza A (H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. Clin Infect Dis. 2011;52(3):422–426.
   PubMed Web of Science ®Google Scholar
• Kalimuddin S, Sessions OM, Hou Y, et al. Successful clearance of human parainfluenza virus type 2 viraemia with intravenous ribavirin and immunoglobulin in a patient with acute myocarditis. J Clin Virol. 2013;56(1):37–40.
   PubMed Web of Science ®Google Scholar
• Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919–922.
   PubMed Web of Science ®Google Scholar
• Planitzer CB, Modrof J, Kreil TR. West Nile virus neutralization by US plasma-derived immunoglobulin products. J Infect Dis. 2007;196(3):435–440.
   PubMed Web of Science ®Google Scholar
• Vassilenko SM, Vassilev TL, Bozadjiev LG, et al. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet. 1990;335(8692):791–792.
   PubMed Web of Science ®Google Scholar
• Kubar A, Haciomeroglu M, Ozkul A, et al. Prompt administration of Crimean-Congo hemorrhagic fever (CCHF) virus hyperimmunoglobulin in patients diagnosed with CCHF and viral load monitorization by reverse transcriptase-PCR. Jpn J Infect Dis. 2011;64(5):439–443.
   PubMed Web of Science ®Google Scholar
• Enria DA, Briggiler AM, Sánchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 2008;78(1):132–139.
   PubMed Web of Science ®Google Scholar
• Garcia A, Diego L, Judith B. New approaches to Chikungunya virus vaccine development. Recent Pat Inflamm Allergy Drug Discov. 2015;9:31–37.
   PubMedGoogle Scholar
• Igarashi A, Fukuoka T, Fukai K. Passive immunization of mice with rabbit antisera against Chikungunya virus and its components. Biken J. 1971;14(3):353–355.
   PubMedGoogle Scholar
• Chaichana P, Okabayashi T, Puiprom O, et al. Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients. PLoS One. 2014;9(3):e92173.
   Google Scholar
• Aguiar M, Stollenwerk N, Halstead SB. The impact of the newly licensed dengue vaccine in endemic countries. Plos Negl Trop Dis. 2016;10(12):e0005179.
   PubMed Web of Science ®Google Scholar
• Passi D, Sharma S, Dutta SR, et al. Zika virus diseases - the new face of an ancient enemy as global public health emergency (2016): brief review and recent updates. Int J Prev Med. 2017;8:6.
   PubMed Web of Science ®Google Scholar
• Keasey SL, Pugh CL, Jensen SM, et al. Antibody responses to Zika virus infections in flavivirus-endemic environments. Clin Vaccine Immunol. 2017;24:e00036-17.
   Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389(10068):505–518.
   PubMed Web of Science ®Google Scholar
• Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, et al. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis. 1999;179(Suppl 1):S218–S23.
   PubMed Web of Science ®Google Scholar
• Emond RT, Evans B, Bowen ET, et al. A case of Ebola virus infection. Br Med J. 1977;2(6086):541–544.
   PubMed Web of Science ®Google Scholar
• Gulland A. First Ebola treatment is approved by WHO. BMJ. 2014;349:g5539.
   PubMed Web of Science ®Google Scholar
• Burnouf T, Dye JM, Ambe J, et al. Convalescent Ebola plasma: assessing neutralizing antibodies at the right stage. Vox Sang. 2016;111(4):456–457.
   PubMed Web of Science ®Google Scholar
• Winkler AM, Koepsell SA. The use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus disease. Curr Opin Hematol. 2015;22(6):521–526.
   PubMed Web of Science ®Google Scholar
• Cao RY, Dong DY, Liu RJ, et al. Human IgG subclasses against enterovirus type 71: neutralization versus antibody dependent enhancement of infection. PLoS One. 2013;8(5):e64024.
   Google Scholar
• Arnon SS, Schechter R, Maslanka SE, et al. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354(5):462–471.
   PubMed Web of Science ®Google Scholar
• Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37(3):333–340.
   PubMed Web of Science ®Google Scholar
• Granstrom M, Olinder-Nielsen AM, Holmblad P, et al. Specific immunoglobulin for treatment of whooping cough. Lancet. 1991;338(8777):1230–1233.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Vaudry W, Boucher FD, et al. Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet. Pediatr Infect Dis J. 2007;26(1):79–81.
   PubMed Web of Science ®Google Scholar
• Han X, Li S, Lu S, et al. Amplification of 16S rDNA by nested PCR for measurement of Mycoplasma pneumoniae DNA over time: clinical application. J Med Microbiol. 2012;61(Pt 3):426–430.
   PubMed Web of Science ®Google Scholar
• Bloom B, Schelonka R, Kueser T, et al. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J. 2005;24(10):858–866.
   PubMed Web of Science ®Google Scholar
• DeJonge M, Burchfield D, Bloom B, et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr. 2007;151(3):260–5, 5 e1.
   PubMed Web of Science ®Google Scholar
• Mytle N, Hopkins RJ, Malkevich NV, et al. Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother. 2013;57(11):5684–5692.
   PubMed Web of Science ®Google Scholar
• Lachmann RA, van Kaam AH, Haitsma JJ, et al. Immunoglobulin M-enriched intravenous polyclonal immunoglobulins reduce bacteremia following Klebsiella pneumoniae infection in an acute respiratory distress syndrome rat model. Exp Lung Res. 2004;30(4):251–260.
   PubMed Web of Science ®Google Scholar
• Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control. 2007;35(2):131–137.
   PubMed Web of Science ®Google Scholar
• Abougergi MS, Broor A, Cui W, et al. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med. 2010;5(1):E1-E9.
   Google Scholar
• McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006;49(5):640–645.
   PubMed Web of Science ®Google Scholar
• Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;53(5):882–884.
   PubMed Web of Science ®Google Scholar
• Shirkey HC. Tetanus immune globulin (human) in prophylaxis against tetanus. J Pediatr. 1965;67(4):643–646.
   PubMed Web of Science ®Google Scholar
• Forrat R, Dumas R, Seiberling M, et al. Evaluation of the safety and pharmacokinetic profile of a new, pasteurized, human tetanus immunoglobulin administered as sham, postexposure prophylaxis of tetanus. Antimicrob Agents Chemother. 1998;42(2):298–305.
   PubMed Web of Science ®Google Scholar
• Agarwal M, Thomas K, Peter JV, et al. A randomized double-blind sham-controlled study of intrathecal human anti-tetanus immunoglobulin in the management of tetanus. Natl Med J India. 1998;11(5):209–212.
   PubMed Web of Science ®Google Scholar
• Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 1980;69(4):567–570.
   PubMed Web of Science ®Google Scholar
• Schedel I, Dreikhausen U, Nentwig B, et al. Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med. 1991;19(9):1104–1113.
   PubMed Web of Science ®Google Scholar
• Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007;35(12):2693–2701.
   PubMed Web of Science ®Google Scholar
• Gokalp AS, Toksoy HB, Turkay S, et al. Intravenous immunoglobulin in the treatment of Salmonella typhimurium infections in preterm neonates. Clin Pediatr (Phila). 1994;33(6):349–352.
   PubMed Web of Science ®Google Scholar
• Nagington J, Gandy G, Walker J, et al. Use of normal immunoglobulin in an echovirus 11 outbreak in a special-care baby unit. Lancet. 1983;2(8347):443–446.
   PubMed Web of Science ®Google Scholar
• Weisman LE, Stoll BJ, Kueser TJ, et al. Intravenous immune globulin therapy for early-onset sepsis in premature neonates. J Pediatr. 1992;121(3):434–443.
   PubMed Web of Science ®Google Scholar
• Jenson HB, Pollock BH. Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics. 1997;99(2):E2.
   Google Scholar
• Fanaroff AA, Korones SB, Wright LL, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 1994;330(16):1107–1113.
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev. 2000;2:CD000361.
   Google Scholar
• Sandberg K, Fasth A, Berger A, et al. Preterm infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G. J Pediatr. 2000;137(5):623–628.
   PubMed Web of Science ®Google Scholar
• Douzinas EE, Pitaridis MT, Louris G, et al. Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. Crit Care Med. 2000;28(1):8–15.
   PubMed Web of Science ®Google Scholar
• Pilz G, Kreuzer E, Kaab S, et al. Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients. Chest. 1994;105(1):76–82.
   PubMed Web of Science ®Google Scholar
• Buda S, Riefolo A, Biscione R, et al. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery. J Cardiothorac Vasc Anesth. 2005;19(4):440–445.
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Rello J, Neira J, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock. 2005;23(4):298–304.
   PubMed Web of Science ®Google Scholar
• Kreymann KG, de Heer G, Nierhaus A, et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock*. Crit Care Med. 2007;35(12):2677–2685.
   PubMed Web of Science ®Google Scholar
• Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care. 2005;20(3):239–249.
   PubMed Web of Science ®Google Scholar
• Bruss JB, Malley R, Halperin S, et al. Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. Pediatr Infect Dis J. 1999;18(6):505–511.
   PubMed Web of Science ®Google Scholar
• Bruss JB, Siber GR. Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model. Clin Diagn Lab Immunol. 1999;6(4):464–470.
   PubMedGoogle Scholar
• Ichimaru T, Ohara Y, Hojo M, et al. Treatment of severe pertussis by administration of specific gamma globulin with high titers anti-toxin antibody. Acta Paediatr. 1993;82(12):1076–1078.
   PubMed Web of Science ®Google Scholar
• Bressan S, Mion T, Andreola B, et al. Severe Mycoplasma pneumoniae-associated mucositis treated with immunoglobulins. Acta Paediatr. 2011;100(11):e238–e40.
   Google Scholar
• Arkilo D, Pierce B, Ritter F, et al. Diverse seizure presentation of acute Mycoplasma pneumoniae encephalitis resolving with immunotherapy. J Child Neurol. 2014;29(4):564–566.
   PubMed Web of Science ®Google Scholar
• Calvano RA, Scacchi MF, Sojo MM, et al. Toxic epidermal necrolysis associated with acute infection by Mycoplasma pneumoniae. Arch Argent Pediatr. 2013;111(1):e24–7.
   Google Scholar
• Park IH, Choi Du Y, Oh YK, et al. A case of acute myopericarditis associated with Mycoplasma pneumoniae infection in a child. Korean Circ J. 2012;42(10):709–713.
   PubMed Web of Science ®Google Scholar
• Tezer H, Kara A, Haliloglu G, et al. Mycoplasma pneumoniae-associated transverse myelitis with unexpected rapid response to macrolide therapy: a case report. Turk J Pediatr. 2008;50(6):585–588.
   PubMed Web of Science ®Google Scholar
• Attilakos A, Palaiologou P, Lagona E, et al. Mycoplasma pneumoniae encephalopathy: recovery after intravenous immunoglobulin. Pediatr Neurol. 2008;38(5):357–359.
   PubMed Web of Science ®Google Scholar
• Salliot C, Zeller V, Puechal X, et al. Panton-Valentine leukocidin-producing Staphylococcus aureus infections: report of 4 French cases. Scand J Infect Dis. 2006;38(3):192–195.
   PubMed Web of Science ®Google Scholar
• Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis. 2002;8(8):833–841.
   PubMed Web of Science ®Google Scholar
• Enserink M. Anthrax. ‘Borrowed immunity’ may save future victims. Science. 2002;295(5556):777.
   PubMed Web of Science ®Google Scholar
• Hendricks KA, Wright ME, Shadomy SV, et al. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2).
   PubMedGoogle Scholar
• Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis. 2007;44(7):968–971.
   PubMed Web of Science ®Google Scholar
• Balakrishna K, Tuteja U, Murali HS, et al. Application of r-PFE hyperimmune sera for concurrent detection of Bacillus anthracis, Yersinia pestis and staphylococcal enterotoxin B. J Appl Microbiol. 2014;116(6):1465–1473.
   PubMed Web of Science ®Google Scholar
• Gorantala J, Grover S, Rahi A, et al. Generation of protective immune response against anthrax by oral immunization with protective antigen plant-based vaccine. J Biotechnol. 2014;176:1–10.
   PubMed Web of Science ®Google Scholar
• Makam SS, Kingston JJ, Harischandra MS, et al. Protective antigen and extractable antigen 1 based chimeric protein confers protection against Bacillus anthracis in mouse model. Mol Immunol. 2014;59(1):91–99.
   PubMed Web of Science ®Google Scholar
• Chandrasekar T, Naqvi N, Waddington A, et al. Intravenous immunoglobulin therapy for refractory Clostridium difficile toxin colitis in chronic kidney disease: case reports and literature review. NDT Plus. 2008;1(1):20–22.
   PubMedGoogle Scholar
• Beales IL. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut. 2002;51(3):456.
   PubMed Web of Science ®Google Scholar
• Murphy C, Vernon M, Cullen M. Intravenous immunoglobulin for resistant Clostridium difficile infection. Age and Ageing. 2006;35(1):85–86.
   PubMed Web of Science ®Google Scholar
• Koulaouzidis A, Tatham R, Moschos J, et al. Successful treatment of Clostridium difficile colitis with intravenous immunoglobulin. J Gastrointestin Liver Dis: JGLD. 2008;17(3):353–355.
   Web of Science ®Google Scholar
• Grover S, Hamilton MJ, Carr-Locke DL. Refractory Clostridium difficile-associated diarrhea. MedGenMed. 2007;9(2):46.
   PubMedGoogle Scholar
• Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg. 1991;45(3):297–308.
   PubMed Web of Science ®Google Scholar
• Gysin J, Moisson P, Pereira Da Silva L, et al. Antibodies from immune African donors with a protective effect in Plasmodium falciparum human infection are also able to control asexual blood forms of the parasite in Saimiri monkeys. Res Immunol. 1996;147(6):397–401.
   PubMedGoogle Scholar
• Taylor TE, Molyneux ME, Wirima JJ, et al. Intravenous immunoglobulin in the treatment of paediatric cerebral malaria. Clin Exp Immunol. 1992;90(3):357–362.
   PubMed Web of Science ®Google Scholar
• Olivieri BP, Vasconcellos R, Nobrega A, et al. Intravenous immunoglobulin increases survival time in the acute phase of experimental Chagas disease. Parasite Immunol. 2010;32(6):464–469.
   PubMed Web of Science ®Google Scholar
• Price H, Genereux M, Sinclair C. Hyperimmune Immunoglobulin G. In: Bertolini J, Goss N, Curling J, editors. Production of plasma proteins for therapeutic use. Hoboken NJ, USA: Wiley; 2012. p. 207–216.
   Google Scholar